Study: Intracranial bleeding risk lower in rivaroxaban users

02/3/2012 | Family Practice News

A sub-analysis of the ROCKET-AF trial showed that patients with atrial fibrillation who took the new anticoagulant rivaroxaban to prevent stroke were 40% less likely to have intracranial hemorrhages than warfarin users. Researchers also found that adding clopidogrel to either warfarin or rivaroxaban increased the risk of intracranial bleeding by 250% compared with clopidogrel or warfarin alone.

View Full Article in:

Family Practice News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC